|
10.01.2025 09:47:59
|
Upgrade of revenue and operating profit guidance
ANNOUNCEMENT NO. 286
10 January 2025
Upgrade of revenue and operating profit guidance
ChemoMetec sustained its positive performance in the second quarter of 2024/25 with better-than-expected sales and order intake. The positive development is supported by the strengthening of the US Dollar and continuous optimisation of operating costs.
Based on this, the Company now expects revenue for the 2024/25 financial year in the DKK 470-490 million range, up from DKK 460-475 million in the most recent guidance, and EBITDA in the DKK 250-260 million range, up from DKK 230-240 million previously.
ChemoMetec’s half-year financial report for 2024/25 is scheduled to be released on Wednesday, 5 February 2025.
Additional information
Martin Helbo Behrens, CEO
Tel.: (+45) 48 13 10 20
Kim Nicolajsen, CFO
Tel.: (+45) 48 13 10 20
About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements.
ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.
ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.
Nachrichten zu ChemoMetec A-S
|
10.01.25 |
Upgrade of revenue and operating profit guidance (GlobeNewswire) | |
|
03.12.24 |
Upgrade of revenue and operating profit guidance (GlobeNewswire) | |
|
22.10.24 |
Closing of acquisition of Ovizio Imaging Systems SA (GlobeNewswire) | |
|
16.10.24 |
Acquisition of Ovizio Imaging Systems SA (GlobeNewswire) | |
|
16.10.24 |
Upgrade of revenue and operating profit guidance (GlobeNewswire) | |
|
11.10.24 |
ChemoMetec’s potential acquisition of Ovizio Imaging Systems SA (GlobeNewswire) |
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
✅ SAP
✅ Dollarama
✅ Waste Connections
Pünktlich zum Börsenstart diskutieren Investment-Stratege François Bloch und Börsen-Experte David Kunz oder Olivia Hähnel über ausgewählte Top-Aktienwerte aus dem BX Musterportfolio.
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| ChemoMetec A-S | 75.95 | -0.65% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Zoll-Schock: SMI und DAX vorbörslich im Minus -- Asiatische Indizes uneinigDer heimische und deutsche Aktienmarkt dürften sich am Dienstag in der Verlustzone bewegen. Am Dienstag finden die wichtigsten asiatischen Märkten keine gemeinsame Richtung.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |